Latest Conference Articles

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

From lifestyle-only approaches to fears about memory, an expert outlines the statin misconceptions pharmacists are most likely to hear.

A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.

A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.

Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.

Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.

Ramantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.

A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.

New BCMA bispecific shows durable myeloma responses with low severe CRS/ICANS, fewer infections, and convenient outpatient dosing in TRAVINO.

In a Swedish study of 482,000 heart failure hospitalizations, cold effects emerged days later, whereas heat effects appeared almost immediately.

Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.

Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.

A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.

At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.

Experts from the NEIAP 2026 Annual Forum share how pharmacists are driving hypertension, lipid, cardiorenal, obesity, and CDTM care as primary clinical decision-makers.

Bola Olagunju, PharmD; and Vicki Saengkheune, PharmD, stress that medication is an important tool in the care of patients with obesity, and improving one disease state can help others improve as well.

Katelyn O'Brien, PharmD, emphasizes sick-day management and preprocedure holds to lower euglycemic DKA risk with sodium-glucose cotransporter 2 (SGLT2) inhibitors.

With a dual glucose-ketone monitor now available, pharmacists must interpret the data and give patients a clear DKA action plan, Goldman says.

Kelsey Norman, PharmD, says addressing provider inertia and asking about adherence at every visit are central to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor success.

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

Updated guidelines call for earlier primary aldosteronism screening in stage 2 hypertension, opening a clear role for pharmacists, says Anthony Ishak.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Vicki Saengkheune, PharmD; and Bola Olagunju, PharmD, describe a collaborative clinic where pharmacists titrate therapy, provide counseling, and remove access barriers.

Jackie Burke, PharmD, has advice for strengthening collaborative drug therapy management (CDTM) in a year: ask leaders what they need, then pilot one focused, trackable, reportable workflow.

Jackie Burke, PharmD, says the widest collaborative drug therapy management (CDTM) gap is operational—implementing workflows and showing outcomes, not proving pharmacists' clinical expertise.

The strongest antiobesity medication candidates are chosen by overall health and comorbidities like heart failure, CKD, and sleep apnea, not weight alone.

Katelyn O'Brien, PharmD, says a shared view of cardio-kidney-metabolic syndrome lets pharmacists unify care across endocrinology, cardiology, and nephrology.